Tesamorelin cost in 2026: brand Egrifta SV vs compounded, and why the gap is so big

Tesamorelin is the rare peptide where the question “how much does it cost?” has two honest answers that are an order of magnitude apart — for the same molecule. On one side is Egrifta SV, an FDA-approved biologic with a specialty-drug price tag. On the other is compounded tesamorelin, dispensed by longevity and telehealth clinics, plus the gray-market “research” vials sold as powders. The reason those two worlds barely touch on price has almost nothing to do with the peptide itself and everything to do with regulatory status, manufacturing, and who is footing the bill. This page maps the cost by route, explains why the gap exists, and is blunt about the catch most cost guides skip: the affordable version is being used off-label for goals the approved version was never tested for.

Why tesamorelin has two prices for one molecule

Most peptide-cost confusion comes from treating “tesamorelin” as a single product. It isn’t. Egrifta SV is a manufactured biologic that earned FDA approval for a narrow, specific use: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.^[1] Approval like that requires the full apparatus — pivotal randomized trials, a manufacturing standard, post-market commitments — and the product is made for a small patient population. That combination, not any special sophistication in the peptide sequence, is what places it in the specialty-biologic price tier. We cover what those trials actually showed in the tesamorelin (Egrifta) evidence review; here the point is narrower: a rare-indication, fully-regulated biologic is expensive to bring to a patient, and the sticker reflects that pipeline.

Compounded tesamorelin is a different transaction entirely. A licensed compounding pharmacy prepares the peptide to a prescriber’s order, sidestepping the branded biologic’s pricing and distribution. The molecule may be the same; the regulatory and commercial scaffolding around it is not. And the gray-market “research-use-only” vial removes even the pharmacy and the prescription from the equation — which is exactly why its sticker looks so low and why that low number is the least trustworthy figure on the page. For the broader framing of how compounded, brand, clinic, and gray-market peptides price against each other, see our peptide therapy cost breakdown; this page goes deep on tesamorelin specifically.

Brand Egrifta SV: a specialty biologic, reached through insurance

Egrifta SV is not a drug most people pay for out of pocket like a telehealth subscription. Its list price lives in the specialty-biologic band — the tier of medicines whose monthly cost runs into the thousands of dollars — and the realistic path to it is a prescription for the approved indication, run through insurance, with the manufacturer’s patient-support program absorbing much of what a covered patient would otherwise owe. The approved status and product details are documented in the current prescribing information.^[2] We deliberately do not quote an exact wholesale figure: specialty list prices move, real out-of-pocket cost depends almost entirely on a given plan’s formulary tier and any copay assistance, and a single “Egrifta SV price” number would be misleading. What is durable is the category: this is a high-cost specialty biologic, not a cash-pay wellness peptide.

Compounded tesamorelin: a few hundred dollars a month

Through longevity-oriented telehealth and clinic channels, compounded tesamorelin generally lands in the low-hundreds-of-dollars-per-month range — commonly somewhere around $300 to $600 a month as of mid-2026, with the spread driven by the prescribed dose, the length of plan you commit to, and whether the program bundles clinician visits and labs. That is a fraction of the brand’s specialty-tier cost, and the difference is almost entirely the regulatory and manufacturing scaffolding described above, not the peptide. Because the prescribed amount drives the bill, your effective monthly cost is inseparable from how you dose — the practical mg-per-day math is laid out in our tesamorelin dosage guide, and it is the single biggest lever on what you actually spend.

It’s worth comparing this against the cheaper, more entrenched GHRH peptide that telehealth sells: sermorelin typically runs lower per month than compounded tesamorelin, which is part of why clinics often position the two as a step-up. We break that trade-off down in tesamorelin vs sermorelin and price the cheaper option directly in our sermorelin cost guide. If a clinic is charging a large premium over these bands, you are paying for the program — consults, labs, an injection kit, and adjacent upsells — rather than for a scarcer drug.

The “research peptide” sticker: cheapest number, highest uncertainty

Search tesamorelin and you’ll find vials sold as powder “for research use only,” advertised at a small fraction of the compounded clinic price. That gap is the entire sales pitch, and it is also the warning. These products sit outside the prescription and compounding-pharmacy system, so nothing verifies that the vial contains tesamorelin at the labeled dose, free of contaminants. The clearest evidence for how badly that can go comes from the adjacent, better-surveilled gray market for GLP-1 drugs: when researchers actually purchased and lab-tested semaglutide products sold online without a prescription, they documented unregistered sellers, orders that never arrived, and analyzed content that diverged from the label.^[3] A tesamorelin powder bought the same way carries the same structural hazard — a low price attached to an unverified product isn’t a discount, it’s an unpriced risk. (To be explicit: that’s a cost-versus-risk observation, not a recommendation to source peptides this way.)

Is tesamorelin worth the cost?

For the approved use, the math is straightforward: in HIV-associated lipodystrophy, tesamorelin has randomized, placebo-controlled trial support for reducing visceral adipose tissue,^[1] and a follow-on analysis found that the visceral-fat reduction tracked with an improved metabolic profile.^[4] When a covered patient reaches it through insurance and the manufacturer’s program, the cost question is largely answered by the formulary. The harder value question is the off-label one — paying a few hundred dollars a month, out of pocket, for compounded tesamorelin toward body composition or longevity goals. There, the honest accounting is that you are buying a drug whose efficacy evidence comes entirely from a different population (people with HIV-associated lipodystrophy) and a specific endpoint (visceral fat), with the healthy-adult anti-aging case still largely an extrapolation. You should also price in the monitoring tesamorelin warrants, since raising the GH/IGF-1 axis is not consequence-free — see our tesamorelin side effects guide.

The honest bottom line

“How much does tesamorelin cost” has no single answer because there is no single tesamorelin market. Brand Egrifta SV is a specialty biologic in the thousands of dollars a month, realistically reached only through insurance for its approved HIV-lipodystrophy indication. Compounded tesamorelin for off-label use runs roughly $300–$600 a month, dose-dependent, paid cash. And the gray-market vial that looks cheapest is the one transaction where the sticker hides the real cost. The gap between these worlds is a story about regulation and who pays, not about a better molecule — so the smart move is to decide which version your goal actually justifies, and to anchor whatever you pay to the evidence rather than the marketing. To compare the legitimate clinics that prescribe GHRH peptides on price and care model, see our peptide therapy provider comparison.